Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression()

INTRODUCTION: Older patients are at higher risk of chemotherapy-induced toxicity, raising interest in less toxic anti-HER2 regimens for older persons with HER2-positive (HER2+) metastatic breast cancer (MBC). PATIENTS AND METHODS: This phase II study randomized (1:1) patients with HER2+ MBC, aged 70...

Descripción completa

Detalles Bibliográficos
Autores principales: Wildiers, Hans, Meyskens, Thomas, Marréaud, Sandrine, Lago, Lissandra Dal, Vuylsteke, Peter, Curigliano, Giuseppe, Waters, Simon, Brouwers, Barbara, Meulemans, Bart, Sousa, Berta, Poncet, Coralie, Brain, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157551/
https://www.ncbi.nlm.nih.gov/pubmed/35636341
http://dx.doi.org/10.1016/j.breast.2022.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157551/
https://www.ncbi.nlm.nih.gov/pubmed/35636341
http://dx.doi.org/10.1016/j.breast.2022.05.004

Ejemplares similares